Healthcare
Surrozen, Inc.(SRZNW)
Live Price
Offline$0.0101
-24.63% today
1Y Change
-14.14%
Window
Jun 25, 2025 โ Jun 9, 2026
- Market Cap
- $250.00M
- Revenue Growth
- -67.4%
- EPS Growth
- -49.4%
- Dividend Yield
- 0.0%
Coverage: 161 bars ยท Jun 25, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Surrozen, Inc. (SRZNW) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $0.01 and down 14.1% across the available one-year price window (Jun 25, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of -67.4%, EPS growth of -49.4%, a dividend yield of 0.0%. What stands out right now is revenue -67.4%, EPS -49.4%, free cash flow -72.0% with operating margin -1210.6% and ROIC -46.7%. Valuation already assumes a fairly strong business story at price/sales 72.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRZNW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-67.4% vs +7.6% peer median
Operating Margin
Below sector median
-1210.6% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -67.4% and EPS is at -49.4%, with operating margin around -1210.6%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.7% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +0.0% | +0.0% | โ |
2026 Mar 23, 2026 | -1385.8% | +0.0% | +0.0% | +0.0% |
2025 Nov 7, 2025 | -636.5% | -18.2% | -5.2% | +74.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRZNW
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SRZNW Max Drawdown
-81.33%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SRZNW and SPY.
Company Overview
Surrozen, Inc.
NASDAQ Capital Market
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies to engage the body's existing biological repair mechanisms with potential application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 that stimulates hepatocyte regeneration, improves liver function, and reduces fibrosis; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are highly expressed in intestinal crypts. The company was founded in 2016 and is headquartered in South San Francisco, California.
- Leadership
- Craig C. Parker
- IPO Date
- Aug 10, 2021
- Employees
- 40
- Street Address
- 171 Oyster Point Boulevard
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 489 9000
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 72.3
- Price/Book
- โ
Growth
- Revenue
- -67.4%
- EPS
- -49.4%
- Free Cash Flow
- -72.0%
Profitability
- Gross Margin
- 98.7%
- Operating Margin
- -1210.6%
- Net Margin
- -6960.8%
- ROE
- 610.8%
- ROIC
- -46.7%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 9.22
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.